With generative AI powering personalized insights, Dexcom’s new Stelo CGM enters the market as the first FDA-cleared over-the-counter …
With generative AI powering personalized insights, Dexcom’s new Stelo CGM enters the market as the first FDA-cleared over-the-counter …
Blending single-cell biology with generative AI, Cellarity launches its first-in-human trial for CLTY-101—an engineered cell therapy targeting tumor …
From decentralized designs to ethical reform, the NIH Pragmatic Trials Collaboratory closes 2024 with a blueprint for smarter, …
With its first-in-class mechanism and monthly dosing, Depemokimab sets a new benchmark in biologic treatment for high-burden asthma …
Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory …
Roche’s PD-L1 inhibitor demonstrates durable response in RET-mutant thyroid cancer, offering a new option for patients with limited …
Pfizer’s ambitious gene therapy for Duchenne muscular dystrophy fails to meet efficacy targets, prompting strategic retreat and industry-wide …
Semaglutide’s latest trial reveals significant reduction in heart failure hospitalizations, expanding its role in cardiometabolic care.
Regulatory approval marks a pivotal moment for psychedelic medicine, as COMPASS Pathways prepares to test psilocybin in treatment-resistant …
GSK’s long-acting biologic reduces exacerbations and improves lung function in eosinophilic asthma, offering a potential once-yearly treatment option.
